Cambridge, United States
eGenesis, founded in 2015 and headquartered in the United States, is a forward-thinking company in the Biopharma, Biotechnology, and Life Sciences sectors. The company has developed an unmatched gene editing platform focusing on creating human-compatible organs, tissues, and cells. Their slogan, "Restoring life after organ failure," encapsulates their mission to address the global organ shortage crisis, providing an innovative and scalable alternative to traditional allotransplantation.
Through the revitalization of xenotransplantation, eGenesis is overcoming historical virology and immunology challenges, steering the industry towards the production of commercially-viable transplant products. Their efforts have garnered significant attention from investors, with a recent $191.00M Series D investment led by prominent names such as Lux Capital, Arch Venture Partners, and Khosla Ventures, among others. This investment underscores their potential in solving a critical healthcare challenge.
